AstraZeneca

In blood cancer, assessing treatment response can be complex, even when there are no visible signs of disease. Minimal residual disease (MRD) testing is becoming an important area of progress and as technology continues to advance, it has the potential to inform prognosis, guide treatment decisions and accelerate drug development. Find out more about how we are working across our haematology portfolio and with partners to advance the science of MRD: https://lnkd.in/eRByszRZ

Congratulations to Chloë Smithers on being named Role Model of the Year: Business, and to Ferne Clark on being recognised as a finalist at The Queer Student Awards 2026! These achievements recognise Chloë and Ferne's commitment to creating a more inclusive workplace, supporting others to bring their authentic selves to work, and making a positive impact across our LGBTQ+ community. #QSA2026 #LifeAtAstraZeneca

On World Bronchiectasis Day, attention turns to a complex and heterogeneous respiratory disease that continues to present significant unmet need. By continuing to explore the underlying drivers of disease, including chronic infection and inflammation, our research aims to help shape a future where better care options may become possible. #WorldBronchiectasisDay

Want to get a behind-the-scenes look at a global biopharmaceutical company, build your personal brand, expand your professional network and gain new friendships? 🚀 Applications for the AstraZeneca Ambassadors Program 2026/2027 are now open! Join our Program and take part in an intensive, one-semester journey (October–February). What’s in it for you? ✨ mentoring & development sessions ✨ collaborating with AstraZeneca teams and expanding your network ✨ growing your presence on LinkedIn (we’ll show you how!) ✨ co-creating events for students Apply by 22 July 2026- https://lnkd.in/db4BjEkj Want to learn more before applying? Join our open webinar: 📅 20 July 🕓 16:30 🔗 https://lnkd.in/ddRTTSJ8 No registration needed – just click and join. We’ll be happy to walk you through the program and answer all your questions 💬 #AZmbassadors #LifeAtAstraZeneca

Your heart and kidneys are more connected than you might think. A common misconception in cardiovascular care is that heart disease and kidney disease are separate problems, but the reality is far more complex. Swipe through to find out why, and what it means for patient outcomes. #cardiology #hearthealth

Many diseases are driven by something specific inside the body, such as a gene or protein, not working as it should. These are called “drug targets”. By using innovative approaches to pinpoint them, scientists can identify root causes of disease and design medicines that can act where they’re needed to restore normal function. This is the first step toward advancing patient outcomes. #ScienceMadeSimple

AstraZeneca has been named among TIME’s World’s Most Sustainable Companies for the third year running, out of over 5,000 companies assessed worldwide, ranked among the top 3 in pharma. Sustainability is embedded in our strategy and in the way we operate. This recognition reflects progress across our sustainability priorities, helping us build a more resilient, efficient business as we work to deliver life-changing medicines for patients and create a healthier future for people, society and the planet. Thank you to our people and partners for turning our sustainability ambition into action. 🌍 #WhatScienceCanDo #TIME #WorldsMostSustainableCompanies Learn more: https://lnkd.in/eQKV64TF

Lung cancer is the leading cause of cancer-related death worldwide. That’s why our work with Consultorio Amazonas matters. By applying AI to chest x-rays, we can identify incidental pulmonary nodules and prioritise high-risk patients for CT scans – helping enable earlier diagnosis and treatment for patients in Colombia. Details of our partnership are outlined in the film.

AstraZeneca has been recognised in the Gartner Supply Chain Top 25 for the fifth consecutive year. This recognition reflects the strength of our global manufacturing and supply network — and the progress we’re making in innovative manufacturing, intelligent supply, and AI-enabled workforce development to deliver medicines to patients faster, more reliably and more sustainably. #GlobalOperations

Obesity rarely exists in isolation. New findings from the AstraZeneca-sponsored CALOR real-world evidence programme put numbers to what clinicians increasingly recognise: around 87% of people with obesity or overweight in the US already have at least one cardiorenal complication. With type 2 diabetes, that rises to around 99%. Many aren’t even aware until serious damage is done. These data make the case for earlier recognition and intervention —for science designed to change disease trajectories, not just body weight. As understanding of obesity continues to grow, there is an opportunity to move beyond weight alone and towards more comprehensive approaches to cardiometabolic health. Read more about the CALOR study here: https://lnkd.in/eugeb2-c #WhatScienceCanDo